Newron Pharmaceuticals Strengthens IP Portfolio for Evenamide

Newron Pharmaceuticals S.p.A. has announced an expansion of its intellectual property portfolio for its lead compound, evenamide. The European Patent Office has granted a new composition of matter patent (EP4615820) for crystalline forms of evenamide, extending exclusivity in the EU until 2044. This patent covers the forms, their processes, and uses, reinforcing Newron's strategy to protect its key assets.

Evenamide is under investigation in the ENIGMA-TRS Phase III program, enrolling over 1,000 schizophrenia patients. It targets treatment-resistant schizophrenia (TRS) as an add-on therapy. Evenamide's unique glutamate modulation addresses a significant unmet need for patients unresponsive to current antipsychotic therapies.

CEO Stefan Weber emphasized the milestone, noting the patent strengthens evenamide’s therapeutic and commercial trajectory as it continues pivotal clinical studies. This development aims to maximize potential benefits for the substantial patient population with schizophrenia.